tbuckley/cabot-search huggingface dataset:
1203O FOLFOX plus nivolumab and ipilimumab versus FOLFOX induction followed by nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Results from the randomized phase II Moonlight trial of the AIO
Authors: S. Lorenzen, P.C. Thuss-Patience, G. Folprecht, J. Riera Knorrenschild, V. Heinemann, E. Goekkurt, T.N. Dechow, T.J. Ettrich, K.B. Luley, J-C. Moulin, U. Lindig, S. Angermeier, O. Waidmann, D. Pink, C. Bolling, S. Junge, C. Pauligk, T. Gaiser, T.O. Götze, S-E. Al-Batran
Journal: Annals of Oncology (2022)
1363MO Cabazitaxel every 2 weeks versus every 3 weeks in older patients with metastatic castration-resistant prostate cancer (mCRPC): The CABASTY randomized phase III trial
Authors: S. Oudard, P. Beuzeboc, E. Voog, P. Barthelemy, A. Thiery-Vuillemin, M. Bennamoun, A. Hasbini, K. Aldabbagh, C. Saldana, E. Sevin, Y.E. Amela, G. Von Amsberg, N. Houede, D. Besson, S. Feyerabend, M. Boegemann, D. Pfister, M. Schostak, O. Huillard, C. Helissey
Journal: Annals of Oncology (2022)
1234P Neoadjuvant camrelizumab plus docetaxel and carboplatin in locally advanced esophageal squamous cell carcinoma (ESCC): A prospective study
Authors: R. Wang, G. Zhang, Q. Zhu, T. Ma, C. Weng, D. Zhang, H. Zeng, T. Wang, F. Gao
Journal: Annals of Oncology (2022)
1292P A review of in-hospital end-of-life care (EOLC) for oncology patients during the COVID-19 pandemic
Authors: H.K. Carroll, A. Broderick, O. McCarthy, M. Kennedy, R. Bambury, D.G. Power, D.C. Collins, R.M. Connolly, S.A. Noonan, D. Collins, E. Cunningham, K. O'Driscoll, D. Nuzum, K. Twomey, A. O'Riordan, F. O'Sullivan, C. Roe, M.J. O'Leary, A.C. Lowney, S. O'Reilly
Journal: Annals of Oncology (2022)
1362MO Pembrolizumab + olaparib vs abiraterone (abi) or enzalutamide (enza) for patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC): Randomized open-label phase III KEYLYNK-010 study
Authors: E.Y. Yu, S.H. Park, J.C.H. Goh, S.J. Shin, N. Mehra, R. McDermott, M.A. Sala Gonzalez, P.C. Fong, R. Greil, M. Retz, J.P. Sade, Y-H. Huang, S. Begbie, F. Rey, G. Kramer, H. Suzuki, J. Zhang, J. Kim, C.H. Poehlein, E.S. Antonarakis
Journal: Annals of Oncology (2022)
1182P US real-world (RW) patient characteristics with METex14 skipping advanced non-small cell lung cancer (aNSCLC)
Authors: R.J. Kelly, X. Le, K. Luttropp, M. Yang, F. Liu, S. Huse, M.L. Ganz, B. Pfeiffer, P.K. Paik
Journal: Annals of Oncology (2022)
1109P Amivantamab vs real-world (RW) therapy in Japanese patients with advanced non-small cell lung cancer (aNSCLC) epidermal growth factor receptor (EGFR) exon-20 insertion mutation (E20i)
Authors: T.M. Kim, N. Girard, G.K.M. Low, J. Zhuo, D.Y. Yu, Y. Yang, M. Murota, C. Lim, N.J. Kleinman, B.C. Cho
Journal: Annals of Oncology (2022)
1209P A phase II study of regorafenib in combination with nivolumab in patients with recurrent or metastatic solid tumors: Results of the ESCC cohort
Authors: L-Y. Bai, C-F. Chiu, S. Kadowaki, M. Robert, H. Hara, M.H. Hong, F. Bergamo, S. Pernot, D. Cunningham, C-Y. Lin, B. Keam, Y. Matsumura, K. Enya, I. Waxman, L. Jin, D. Ngo, U. Drews, C. Mancao, M-A. Le Berre, K. Kato
Journal: Annals of Oncology (2022)
1179P Real-world insights into non-small cell lung cancer patients with MET exon 14 skipping mutations: A Swedish retrospective study from two university hospitals
Authors: M. Skribek, H. Brunnstrom, O. Aricak, M. Planck, K. Jatta, G.N. Oskarsdottir, H. Naserhojati, F. Haglund, S. Ekman
Journal: Annals of Oncology (2022)
1122P An adjusted comparison of amivantamab phase II data versus real-world clinical management in France of EGFR exon 20 insertion-mutated (ex20ins) advanced NSCLC patients
Authors: C. Chouaid, N. Perualila, D. Debieuvre, X. Quantin, J. Diels, N. Rahhali, R. Toueg, G. Simon, L. Bosquet, T. Filleron
Journal: Annals of Oncology (2022)
1249P Older patients experience similar toxicity and survival outcomes to FLOT chemotherapy compared to younger patients
Authors: A.R. Lewis, B.S. Hapuarachi, A.A. Khan, F. Britton, N. Billy Graham Mariam, K. Connors, V. Kounnis, R. Lee, J.M.J. Weaver, K.V. Kamposioras, R. Hubner, T.S. Waddell, W. Mansoor
Journal: Annals of Oncology (2022)
1217P Profiling of myeloid cells associated with prognosis in nivolumab monotherapy for advanced gastric cancer (WJOG10417GTR study)
Authors: H. Shoji, N. Boku, C. Kudo-Saito, K. Nagashima, K. Tsugaru, N. Takahashi, T. Kawakami, Y. Amanuma, T. Wakatsuki, N. Okano, Y. Narita, Y. Yamamoto, R. Kizawa, H. Imazeki, K. Aoki, K. Muro
Journal: Annals of Oncology (2022)
1308P Comparison of tumour size on outcomes for patients with unresectable locally advanced pancreatic adenocarcinoma (LAPC) receiving P-32 microparticles with standard-of-care chemotherapy (SoC CT)
Authors: P. Ross, H.S. Wasan, D. Croagh, M. Nikfarjam, N. Nguyen, M. Aghmesheh, A. Nagrial, D. Bartholomeusz, A. Hendlisz, T. Ajithkumar, C. Iwuji, D.M. Turner, D. James, M. Harris
Journal: Annals of Oncology (2022)
1172P High activity of poziotinib in G778_P780dup HER2 exon 20 insertion mutations in non-small cell lung cancer (NSCLC)
Authors: X. Le, S. Sun, E. Haura, E. Bertino, C. Baik, H. Mamdani, S. Leu, A. Thiagalingam, J. Kokhreidze, F. Lebel, M.A. Socinski
Journal: Annals of Oncology (2022)
1222P Predictiveness of Mandard score on recurrence patterns of esophageal adenocarcinoma after neoadjuvant therapy and surgery
Authors: D. Liu, S.P. Henckens, M.C. Kalff, M.F. Bijlsma, C. Oyarce, S. Gisbertz, H.W.M. van Laarhoven, M.I. van Berge Henegouwen
Journal: Annals of Oncology (2022)
1082P Improved response prediction to immune checkpoint inhibitors by combining TMB and WGS-driven genomic features in NSCLC
Authors: P. Nawrocka-Muszyńska, K. Pacewicz, M. Mędzin, P. Sztromwasser, M. Dąbrowski, D. Sielski, W. Burman, R. Matkowski, P. Kasprzak, S. Szymański, M. Piernik, A. Woźna, P. Zawadzki
Journal: Annals of Oncology (2022)
1210P The preliminary efficacy and safety of KN026 combined with KN046 treatment in HER2-positive locally advanced unresectable or metastatic gastric/gastroesophageal junction cancer without prior systemic treatment in a phase II study
Authors: L. Shen, J. Gong, Z. Niu, R. Zhao, None L. Chen, None L. Liu, T. Deng, None L. Lu, Y. Zhang, None Z. Li, None X. Li, None B. Xia
Journal: Annals of Oncology (2022)
1310MO Neoadjuvant platinum-based chemotherapy (NAPC) for metastatic penile squamous cell carcinoma (PSCC): An international, multicenter, real-world study
Authors: J. Chahoud, A. Mustasam, K.M. Rose, P.E. Spiess, K.L. Moses, V.A. Master, B. Nazha, T.Z. Zhuang, A. Schneider, K. Marchetti, E. Roussel, R.T. Pham, N. Zacharias, L. Pagliaro, C. Hernandez, J. Montrose, C. Alifrangis, M. Albersen, C. Protzel, C. Pettaway
Journal: Annals of Oncology (2022)
1090P HER2 copy number variation in non-small cell lung cancer (NSCLC)
Authors: M. Tagliamento, E. Auclin, A. Valent, R. Ferrara, S. Cotteret, E. Rouleau, C. Caramella, M. Riudavets Melia, A. Gazzah, J. Adam, C. Jovelet, A. Bayle, L. Lacroix, N. Auger, F. Barlesi, D. Planchard, B. Besse, L. Mezquita
Journal: Annals of Oncology (2022)
1101P Use of genomic sequencing for the determination of genomic alterations and new therapeutic opportunities in Spanish lung cancer (LC) patients (pts)
Authors: M.R. Garcia Campelo, E. Arriola, D. Isla, R. Bernabe Caro, D. Perez Parente, B. Moll, J. Lavara Sanz, S. Olson, J. García González
Journal: Annals of Oncology (2022)
1149P Factors associated with not receiving first-line (1L) immune checkpoint inhibitor (ICI) treatment among patients (pts) with advanced NSCLC and high programmed cell death-ligand 1 (PD-L1) expression: An evaluation by age
Authors: J. Feliciano, N. Wu, W. Ge, R. Quek, M. Gleeson, J.J. Jalbert, M.L. Hsu, J. Harnett
Journal: Annals of Oncology (2022)
1252P Update results of anlotinib combined with nab-paclitaxel and cisplatin as neoadjuvant treatment for esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase Ⅱ clinical trial
Authors: Y-F. Zhang, X-B. Li, Y-G. Hong, X-M. Li, W-M. Liang, Z-X. Zheng, G-Y. Yang, Y-Y. Wen, H. Cao, W-L. Wu, W-Z. Su
Journal: Annals of Oncology (2022)
1312O From regulating off-label use to creating an environment for drug repurposing in oncology
Authors: S. van Waalwijk van Doorn-Khosrovani, A. Pisters, E. Breugel, L. Timmers, E.E. Voest, H. Bloemendal, F.A. Eskens, M. Wymenga
Journal: Annals of Oncology (2022)
1150P Progression of advanced non-small cell lung cancer after durable clinical benefit on anti-PD-1/PD-L1 monotherapy: Prolonged post-progression survival and interest of tumor growth rate
Authors: I. Pourmir, R-T. Elaidi, Z. Maaradji, B. Gazeau, L. Gibault, M. Ung, E. Fabre-Guillevin
Journal: Annals of Oncology (2022)
1333P S1 Guideline for prioritisation in gastrointestinal cancer care: Scarcity of resources in the pandemic context
Authors: A. Reinacher-Schick, C. Lugnier, S. Sommerlatte, T. Birkner, O. Schoffer, A-L. Kraeft, S. Foerster, W. Knauf, B.O. Maier, E. Fokas, M. Ebert, P. Piso, K-S. Monika, J. Christmann, R.D. Hofheinz, A. Tannapfel, B.J. Woermann, J. Schmitt, J. Schildmann
Journal: Annals of Oncology (2022)
1170P Updated efficacy and safety data from the phase I/II ARROW study of pralsetinib in patients (pts) with advanced RET fusion+ non-small cell lung cancer (NSCLC)
Authors: B. Besse, F. Griesinger, G. Curigliano, M. Thomas, V. Subbiah, C.S. Baik, D.S.W. Tan, D.H. Lee, E. Garralda, D-W. Kim, A.J. Van Der Wekken, J. Gainor, L. Paz-Ares, S.V. Liu, D.W. Bowles, A. Zalutskaya, T. Ruf, A. Rahman, G. Chen, J. Mazieres
Journal: Annals of Oncology (2022)
1187TiP Phase III study of tislelizumab (TIS) with sitravatinib versus chemotherapy (chemo) in patients with locally advanced/metastatic non-small cell lung cancer (NSCLC) previously treated with chemo and an anti-programmed cell death protein 1/ligand 1 (PD-[L]1) antibody
Authors: Z. Qing, J. Zhao, B. Gao, M. Wang, J. Chang, J. Hu, J. Li, J. Zhang, Q. Zhang, C. Fei, Y-L. Wu
Journal: Annals of Oncology (2022)
1151P Evolution of biomarker testing among non-squamous/non-small cell lung cancer (NSCLC) patients (Pts) and impact on turnaround times (TAT)
Authors: Z. Fan, R. Tudor, L. Le, J. Law, S. Kuang, N. Meti, A. Fung, K. Perdrizet, K. Chen, J. Li, N. Ghumman, L. Ranich, C. Wei, P. Sabatani, M-S. Tsao, N. Leighl, M. Cabanero
Journal: Annals of Oncology (2022)
1309P CD8+ T cell infiltration is associated with improved survival in advanced pancreatic cancer
Authors: G.M. O'Kane, Y.Q. Wang, R. Gonzalez, G. Jang, A. Zhang, A. Dodd, S. Ramotar, S. Hutchinson, F. Vyas, N. Chan, M. Tehfe, R. Ramjeesingh, J. Biagi, J. Wilson, S.E. Fischer, R. Grant, G. Zogopoulos, S. Gallinger, B. Grunwald, J. Knox
Journal: Annals of Oncology (2022)
1219P Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction (G/GEJ) adenocarcinoma: The PANDA study
Authors: M. Chalabi, Y.L. Verschoor, J. Van De Haar, J. van den Berg, L. Kodach, J. van Sandick, J. van Dieren, S. Balduzzi, M.C. Grootscholten, X. Veenhof, K. Hartemink, M. Vollebergh, E. Owers, A. Bartels-Rutten, P. den Hartog-Lievaart, M. van Leerdam, T.N. Schumacher, J.B.A.G. Haanen, E.E. Voest
Journal: Annals of Oncology (2022)
1238P Effect of a standardized nutritional support program on nutritional status, body composition, morbidity and mortality in patients with advanced upper gastrointestinal (UGI) cancer before and after neo-adjuvant radio-chemotherapy followed by surgery
Authors: C. Fottner, M. Silber, L. Bergholz, J. Gartenschläger, R. Gans, M. Ferrata, A. Zimmermann, M. Gartenschläger, T. Bostel, M. Moehler, P. Grimminger, M.M. Weber
Journal: Annals of Oncology (2022)
1135P Adverse event (AE) burden of nivolumab-based immuno-oncology (IO) therapy with/without chemotherapy (chemo) for first-line (1L) advanced non-small cell lung cancer (aNSCLC)
Authors: L. Schwartzberg, A. Wu, J. Hartman, T. Wang, X. Yin, J. Chen, K.A. Betts, S.J. Lubinga
Journal: Annals of Oncology (2022)
1215P Neoadjuvant concurrent chemoradiotherapy combined with immunotherapy in the treatment of adenocarcinoma of the oesophagogastric junction: A phase II study
Authors: R. Du, J. Ming, J. Geng, X. Sui, S. Li, Z. Liu, X. Zhu, Y. Cai, Z. Wang, None L. Tang, X. Zhang, Z. Peng, Y. Yan, Z. Li, Y. Peng, A. Wu, Y. Li, Z. Li, W. Wang, J. Ji
Journal: Annals of Oncology (2022)
1224P Final analysis of clinical outcomes in the DELIVER trial: Observational study of nivolumab treatment in advanced gastric cancer (JACCRO GC-08)
Authors: Y. Sunakawa, E. Inoue, Y. Sakamoto, R. Kawabata, A. Ishiguro, Y. Akamaru, Y. Kito, M. Takahashi, J. Matsuyama, H. Yabusaki, A. Makiyama, T. Suzuki, M. Tsuda, H. Yasui, H. Kawakami, T.E. Nakajima, K. Muro, R. Matoba, W. Ichikawa, M. Fujii
Journal: Annals of Oncology (2022)
1145P Atezolizumab and stereotactic body radiotherapy in patients with advanced non-small cell lung cancer: The ComIT-1 trial
Authors: H. Horndalsveen, T.N. Alver, A.M. Dalsgaard, Å.K. Öjlert, V.D. Haakensen, M.M. Bjaanaes, A. Helland
Journal: Annals of Oncology (2022)
1079P Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with novel actionable oncogenic driver alterations
Authors: T. Beninato, M. Brambilla, C.C. Pircher, L. Mazzeo, A. Rametta, S. Manglaviti, A. De Toma, G. Galli, A. Prelaj, R. Ferrara, C. Proto, G. Lo Russo, M. Ganzinelli, R. Di Mauro, A. Di Nucci, M.C. Garassino, P. Marchetti, F.G.M. De Braud, M. Occhipinti
Journal: Annals of Oncology (2022)
1123P Real-world outcomes of first-line osimertinib for EGFR mutated advanced NSCLC patients in China: Interim analysis of the FLOURISH study
Authors: J. Zhou, J. Zhou, J. Zheng, K. Wang, K. Tang, None D. Lu, J. Cui, D. Zhu, Y. Wang, Y. Zhao, L. Xing, L. Ding, X. Shi, L. Shen
Journal: Annals of Oncology (2022)
1260TiP The efficacy of the addition of TRAstuzumab and Pertuzumab to neoadjuvant chemoradiation: A randomized multi-center study in resectable HER2 overexpressing adenocarcinoma of the esophagus or gastroesophageal junction (TRAP-2)
Authors: D. Blangé, M.C.C.M. Hulshof, M.I. van Berge Henegouwen, B. Mostert, M. Slingerland, N. Haj Mohammad, M.C. Grootscholten, G-J.M. Creemers, L.J.M. Mekenkamp, E. Fiets, J.J. De Haan, P. Jeene, T. Rozema, M. Berbee, A. Beeker, L.V. Beerepoot, S. Derks, M.F. Bijlsma, N. van Grieken, H.W.M. van Laarhoven
Journal: Annals of Oncology (2022)
1181P Heterogeneity and prognostic diagnosis of KRAS-mutated population and KRAS G12C subtype among patients (pts) with advanced NSCLC (aNSCLC): A real-world study aided by machine learning approaches
Authors: H.H.F. Loong, T. Liu, T. Pattipaka, R. Hong, T.W. Smith, S.M. Knoll, V. Pretre, R. Caparica Bitton, F. Ye, A. Farago
Journal: Annals of Oncology (2022)
1111P Real-world treatment duration in patients with non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion (EGFRex20ins) mutations receiving mobocertinib through the global Expanded Access Program (EAP)
Authors: V.H.F. Lee, M. Lin, E. Curran, Y. Yin, E. Churchill, S. Allen, J. Abovich, N. Leighl
Journal: Annals of Oncology (2022)
1091P Predictive and prognostic value of Patras Immunotherapy Score (PIOS) in patients with advanced NSCLC treated with immunotherapy/chemotherapy combination
Authors: F-I.D. Dimitrakopoulos, P. Christopoulos, M. Elshiaty, L. Daniello, I. Pyrousis, A. Kottorou, T. Makatsoris, C. Kalofonos, A. Koutras
Journal: Annals of Oncology (2022)
1130P Real-world data of osimertinib (osi) for the treatment of metastatic epidermal growth factor receptor (EGFR+) non-small cell lung cancer (NSCLC) patients (pts), with a focus on age, body mass index (BMI) and trough levels
Authors: A.V. Veelen, M.G.D. Veerman, M. Verschueren, J. Gulikers, A. Brouns, S. Dursun, R.H. Mathijssen, A-M.C. Dingemans, V.C.G. Tjan-Heijnen, B. Peters, P. Souverein, A. Driessen, L. Hendriks, R. van Geel, S. Croes
Journal: Annals of Oncology (2022)
1197TiP A phase I-II multicenter, open-label, dose-escalation study to evaluate the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of ABN401 in patients with advanced solid tumors and dose-expansion in patients with non-small cell lung cancer harboring c-MET dysregulation
Authors: D.H. Lee, A. Roohullah, B.C. Cho, S-H. Lee, C. Lemech, P. de Souza, M. Millward, J. Choi, K.E. Park, E. Kim, N.Y. Kim, Y.K. Shin, J-Y. Han
Journal: Annals of Oncology (2022)
1244P Prognostic impact of myeloid subsets in nivolumab monotherapy for advanced gastric cancer (WJOG10417GTR study)
Authors: N. Boku, C. Kudo-Saito, H. Imazeki, H. Shoji, K. Tsugaru, N. Takahashi, T. Kawakami, Y. Amanuma, T. Wakatsuki, N. Okano, Y. Narita, Y. Yamamoto, R. Kizawa, K. Nagashima, K. Aoki, K. Muro
Journal: Annals of Oncology (2022)
1205MO Updated analysis of DESTINY-Gastric02: A phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable/metastatic gastric/gastroesophageal junction (GEJ) cancer who progressed on or after trastuzumab-containing regimen
Authors: G.Y. Ku, M. Di Bartolomeo, E. Smyth, I. Chau, H. Park, S. Siena, S. Lonardi, Z.A. Wainberg, J.A. Ajani, J. Chao, F. Barlaskar, Y. Kawaguchi, A. Qin, J. Singh, G. Meinhardt, E. Van Cutsem
Journal: Annals of Oncology (2022)
1346P Diagnosis of early-stage cancers in carriers of BRCA1/2 pathogenetic variants: Two years of activity of the multidisciplinary team for hereditary cancers
Authors: M. Pensabene, S. Greggi, S. Visconti, M.S. Gallo, S. Pignata, S. Mori, F. Avino, R. Saponara, U. Marone, C. Siani, E. Esposito, M.L. Barretta, L. Formisano, C. Roma, D. Barberio, M. De Laurentiis, N. Normanno
Journal: Annals of Oncology (2022)
1236P Comorbidities and their association with the overall survival in a large European cohort with gastroesophageal cancer
Authors: H.C. Puhr, F. Selimi, K. Oberreiter, M.A. Dieterle, C.C. Weirauch, G. Jomrich, M. Paireder, S.F. Schoppmann, A.S.S. Berghoff, M. Preusser, A. Ilhan-Mutlu
Journal: Annals of Oncology (2022)
1206P HER2 copy number variation (CNV), HER2 expression and primary resistance mechanisms in patients (pts) with HER2-positive metastatic gastric or gastroesophageal junction cancer (mGC/GEJC) receiving first-line chemotherapy (CT) + trastuzumab (T) +/- pertuzumab (P) in the JACOB trial
Authors: F. Pietrantonio, E. Berrino, P. Manca, None S.E. Bellomo, A. Raimondi, S. Corso, F. Morano, C. Migliore, M. Niger, C. Marchiò, M. Di Bartolomeo, E. Restuccia, C. Lambertini, J. Tabernero, S. Giordano
Journal: Annals of Oncology (2022)
1171P A phase II theranostic study with osimertinib in patients with EGFR-mutated non-small cell lung cancer (NSCLC) progressing on EGFR tyrosine kinase inhibitors (TKI) and undetectable EGFR T790M (THEROS)
Authors: M. Wiesweg, J. Hense, K. Darwiche, S. Michels, H. Hautzel, C. Kobe, M. Metzenmacher, T. Herold, G. Zaun, K. Laue, A. Drzezga, H-U. Schildhaus, J. Wolf, K. Herrmann, M.H.H. Schuler
Journal: Annals of Oncology (2022)
1261TiP CARMEN-GC01: Phase II, open-label, single-arm study of tusamitamab ravtansine in combination with ramucirumab in pretreated patients with gastric or gastroesophageal junction adenocarcinoma (GA/GEJA)
Authors: F.M. Esposito, J. Lee, S.Y. Rha, K.D. Penkov, A. Moisseev, M. Van Den Eynde, H. Prenen, M. Díez García, M. Gumus, T. Sagawa, M. Nechaeva, T. Kajiwara, H. Harputluoglu, L. Charbonnier, S. Bensfia, N. Yang, D-Y. Oh
Journal: Annals of Oncology (2022)
1174P The MET inhibitor ABN401 in combination with the third-generation EGFR-TKI is effective MET-amplified and EGFR-mutant NSCLC with acquired resistance to third-generation EGFR-TKI in preclinical models
Authors: M.R. Yu, M.R. Yun, S. Lee, N. Rajasekaran, K.E. Park, N.Y. Kim, S. Hong, S.Y. Oh, Y.W. Lee, E.J. Lee, C.G. Kim, S.M. Lim, J. Choi, B.C. Cho
Journal: Annals of Oncology (2022)
1167P Central nervous systemic efficacy of immune checkpoint inhibitors and concordance between intra/extracranial response in non-small cell lung cancer patients with brain metastasis
Authors: S. Kang, H. Jeong, J.E. Park, H.S. Kim, Y-H. Kim, K. Sang-We, J.C. Lee, C-M. Choi, S. Yoon, D.H. Lee
Journal: Annals of Oncology (2022)
1092P Clinical potential of circulating tumor DNA (ctDNA)-based molecular response (MR) and baseline blood-based tumor mutational burden (bTMB) for monitoring response to first-line (1L) chemoimmunotherapy in advanced squamous non-small cell lung cancer (sqNSCLC)
Authors: F. Ciardiello, Z. Feng, N.R. Smith, Z.G. Andric, S. Shell, A. Yablonovitch, G. Guezel, J. Scheuenpflug
Journal: Annals of Oncology (2022)
1125P Real-world molecular testing and treatment patterns in epidermal growth factor receptor (EGFR) mutation-positive, locally advanced or metastatic Chinese non-small cell lung cancer patients failing first-line EGFR-tyrosine kinase inhibitors
Authors: P. Tian, L. Wu, C. Zhou, J. Tan, K. Wang, F. Luo, Y. Liu, Y. Guo, None Y. Li, Z. Liu, Y. Gong, Y. Wang, None W. Li
Journal: Annals of Oncology (2022)
1098P Predictive factors of efficacy to pembrolizumab in advanced NSCLC patients with high PD-L1 expression.
Authors: A. Piedra, A. Barba Joaquín, J. Mosquera Martinez, M. Fernandez Bruno, P. Cordeiro González, I.G. Sullivan, M. Riudavets Melia, M. Aguado Sorolla, P. Gallardo Melo, B. Martin Cullell, J. Gavira, J.C. Tapia, A. Romano, F. Bosma, S. Sanchez Del Rio, J. Sanz Beltran, M.A. Molina Pérez, J. Serra López, M.R. Garcia Campelo, M. Majem Tarruella
Journal: Annals of Oncology (2022)
1263O Evaluation of weight gain and overall survival of male vs. female patients with advanced non-small cell lung cancer (NSCLC) receiving first-line chemotherapy
Authors: E.J. Roeland, F.J. Fintelmann, R. Yang, L.C. Tarasenko, T.D. McRae, J.H. Revkin, P.D. Bonomi
Journal: Annals of Oncology (2022)
1118P Real-world adjuvant treatment patterns in patients with stage I-III EGFR-mutated non-small cell lung cancer (NSCLC) in China: Interim analysis from the ADDRESS study
Authors: W. Liang, S. Jiang, Y. Chai, W. Liu, None L. Liu, P. Song, Z. Wang, S. Zhang, H. Xin, X. Liu, S. Xu, H. Zhang, Y. Han, W. Shen, Z. Peng, M. Geng, G. Yu, X. Zhang, J. He
Journal: Annals of Oncology (2022)
1297P Adjuvant gemcitabine is as efficient as mFOLFIRINOX in patients with GemPred+ tumor signature and resected pancreatic adenocarcinoma (PDAC): An ancillary study of the PRODIGE-24 clinical trial
Authors: R. Nicolle, J-B. Bachet, A. Harlé, J.L. Iovanna, P. Hammel, V. Rebours, A. Turpin, M. Ben Abdelghani, None A. wei, E. Mitry, A. Lopez, J. Biagi, E. Francois, P. Artru, A. Lambert, D.J. Renouf, M. Mauduit, N. Dussetti, T. Conroy, J. Cros
Journal: Annals of Oncology (2022)
1175P Pharmacokinetics of ensartinib in advanced solid tumors and anaplastic lymphoma kinase-positive non-small cell lung cancer
Authors: Y. Xu, D. Ji, P. Pan, T. Li, L-X. Han, Z. Zhang, Y. Wang, H. Li, X-F. Chen, X-J. Zheng, L. Xu, H-X. Liu, Q-H. Meng, M-Z. Wang, Q-S. Zheng
Journal: Annals of Oncology (2022)
1360MO Quality of life and patient-relevant endpoints with darolutamide in the phase III ARASENS study
Authors: K. Fizazi, M.R. Smith, M. Hussain, F. Saad, C. Sternberg, E.D. Crawford, J.B. Aragon-Ching, S. Thiele, S. Kapur, A.F. Mohamed, S. Srinivasan, R. Li, I. Kuss, H. Joensuu, B. Tombal
Journal: Annals of Oncology (2022)
1259TiP Investigator-initiated phase II study of nivolumab plus low-dose ipilimumab as first-line therapy for microsatellite instability—high advanced gastric or esophagogastric junction cancer (NO LIMIT, WJOG13320G/CA209-7W7)
Authors: H. Kawakami, S. Kadowaki, K. Hirata, M. Tsuda, T. Esaki, N. Sugimoto, A. Makiyama, N. Machida, H. Hirano, H. Hara, T. Kawakami, W. Okamoto, H. Yabusaki, Y. Komatsu, S. Hironaka, K. Muro
Journal: Annals of Oncology (2022)
1280P Validation of HAprog, an app for advanced cancer outpatient prognostication in routine practice
Authors: D.D. Preto, M.G.B. Guimarães, E.M. Gonçalves, T.S.D. Alencar, G.A. Zulli, A.G.V. de Melo, C.P. Barone, M.L. Freire, B.S.R. Paiva, C.E. Paiva
Journal: Annals of Oncology (2022)
1131P Overall survival after treatment with first-line crizotinib or alectinib in patients with stage IV NSCLC and ALK rearrangement: A real-world nationwide cohort study from the Netherlands
Authors: M. Tilkema-Tiebosch, R. Damhuis, S. Vijftigschild, A.J. Van Der Wekken
Journal: Annals of Oncology (2022)